Published in Medical Letter on the CDC and FDA, February 22nd, 2004
Data from this clinical trial are now expected in the second quarter of this year and additional components of the NDA filing will be provided to the FDA after these data are available. Tarceva is designed to block tumor cell growth by inhibiting the tyrosine kinase activity of the HER1/EGFR receptor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA